Show simple item record

dc.contributor.authorScibelli, Gennaro
dc.contributor.authorMaio, Lucia
dc.contributor.authorSasso, Maiara
dc.contributor.authorLanza, Alessandro
dc.contributor.authorSavoia, Giorgio
dc.date.accessioned2020-05-25T13:18:55Z
dc.date.available2020-05-25T13:18:55Z
dc.date.issued2017
dc.identifier.citationScibelli G, Maio L, Sasso M, Lanza A, Savoia G. Dexmedetomidine: current role in burn icu. Translational Medicine @ UniSa 2017, 16(1): 1-16.it_IT
dc.identifier.issn2239-9747it_IT
dc.identifier.urihttp://www.translationalmedicine.unisa.it/indexit_IT
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/4490
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-2688
dc.description.abstractDexmedetomidine (DEX) is a relatively recent a2-adrenergic agonist which provides sedation, anxiolysis and analgesia with much less respiratory depression than other sedatives. These characteristics have implemented the use of the drug in the ICUs in order to achieve the target of a “arousable sedation”, thanks to its significant manageability. Its sedative-analgesic properties are also particularly suitable for use in burn ICUs, both adult and pediatric, which is why the current Guidelines have recognized a central role in the management of these categories of patients. Finally, DEX has showed significant anti-inflammatory effect both in animal models and in preliminary clinical trials, reducing vasopressor requirements and main mediators levels of the systemic inflammatory response involved in sepsis and similar processes, suggestingits use for improved outcome in ICU septic patients.it_IT
dc.format.extentP. 1-10it_IT
dc.language.isoenit_IT
dc.sourceUniSa. Sistema Bibliotecario di Ateneoit_IT
dc.subjectDexmedetomidineit_IT
dc.subjectBurnsit_IT
dc.subjectICUit_IT
dc.subjectSepsisit_IT
dc.titleDexmedetomidine: current role in burn ICUit_IT
dc.typeArticleit_IT
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record